Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.78 |
| ▸ | GMPS | P49915 | 2/20 | 0.73 |
| ▸ | FYN | P06241 | 3/20 | 0.67 |
| ▸ | SRC | P12931 | 3/20 | 0.67 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.66 |
| ▸ | VCP | P55072 | 1/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18996626 | 0.90 | EGFR (0.64) | EGFRGMPSFYNSRCERBB2 | |
| SCHEMBL4585990 | 0.88 | EGFR (1.00) | EGFRGMPSERBB2HDAC3HDAC4 | |
| SCHEMBL4354580 | 0.88 | EGFR (0.78) | EGFRGMPSERBB2 | |
| SCHEMBL4585935 | 0.88 | EGFR (1.00) | EGFRGMPSFYNSRCERBB2 | |
| SCHEMBL31318107 | 0.85 | GMPS (1.00) | EGFRGMPSERBB2 | |
| SCHEMBL22971857 | 0.85 | GMPS (1.00) | EGFRGMPSERBB2 | |
| SCHEMBL4588756 | 0.85 | EGFR (0.79) | EGFRGMPSFYNSRCVCP | |
| SCHEMBL27923378 | 0.85 | FYN (0.73) | EGFRFYNSRCERBB2VCP | |
| SCHEMBL8976404 | 0.84 | EGFR (0.69) | EGFRGMPSFYNSRCERBB2 | |
| Hydrochloric Acid SCHEMBL8104687 | 0.84 | EGFR (0.70) | EGFRGMPSERBB2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461166-B2 | Anilinoquinazolinyl amide derivatives; radiolabels as bioprobes for Positron Emission Tomography and Single Photon Emission Computed Tomography, and as radiopharmaceuticals for radiotherapy; improved solubility, bioavailability, biostability | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2013-06-11 | — | — | US | disclosed |
| EP-1594504-A4 | NOVEL IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND USES THEREOF FOR THERAPY AND DIAGNOSIS | T K SIGNAL LTD (IL) | 2008-12-17 | — | — | EP | disclosed |
| EP-1957468-A2 | POLYALKYLENE GLYCOL DERIVATIVES OF 4 - (PHENYLAMINO)QUINAZOLINES USEFUL AS IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE | T.K. Signal Ltd. (IL) | 2008-08-20 | — | — | EP | disclosed |
| US-20080056990-A1 | Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase | T.K. SIGNAL LTD. (IL) | 2008-03-06 | — | — | US | disclosed |
| WO-2007029251-A2 | POLYALKYLENE GLYCOL DERIVATIVES OF 4- (PHENYLAMINO)QUINAZOLINES USEFUL AS IRREVERSIBLE INHIBITORS OF EPIDERMAL GR0WTH FACT0R RECEPTOR TYROSINE KINASE | T.K. SIGNAL LTD. (IL) | 2007-03-15 | — | — | WO | disclosed |
| WO-2006085330-A2 | USE OF PROTEIN TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF LEIOMYOMAS | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2006-08-17 | — | — | WO | disclosed |
| US-20060025430-A1 | Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis | T.K. SIGNAL LTD. (IL) | 2006-02-02 | — | — | US | disclosed |
| EP-1594504-A2 | NOVEL IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND USES THEREOF FOR THERAPY AND DIAGNOSIS | T.K. Signal Ltd. (IL) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004064718-A2 | IRREVERSIBLE INHIBITORS OF EGF RECEPTOR TYROSINE KINASES AND USES THEREOF | T.K. SIGNAL LTD. (IL) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080056990-A1 | Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase | EGFR, TK1, ERBB2 | EGFR 1/4885GMPS 1174/4885FYN 459/4885 |
| US-20060025430-A1 | Novel irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and uses thereof for therapy and diagnosis | EGFR, ERBB2, ERBB3 | EGFR 1/4885GMPS 1976/4885FYN 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.